Versus TB-500 / Thymosin beta-4 (43 AA, dose 2-10 mg): TB-500 acts mainly on the cytoskeleton (G-actin sequestration), cell migration and angiogenesis
The headline results, as released in the Eli Lilly investor communication and aligned with the study design paper by Giblin and colleagues published in Diabetes, Obesity and Metabolism in 2026, are unusually strong for a Phase 3 obesity trial: Retatrutide 12 mg: mean body-weight reduction of 28.7 percent, roughly 32.3 kg (about 71.2 lbs) from baseline
doi:10.1007/s00441019030168
Common insulin syringe capacities are 0.3 mL, 0.5 mL, and 1.0 mL , corresponding to 30, 50, and 100 units of U-100 insulin (U-100 means 100 units per mL)
Side effects are typically minimal with targeted lipo shots
Glucose Intolerance or Diabetes Mellitus Inform patients that treatment with EGRIFTA WR may result in glucose intolerance or diabetes mellitus